<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fphar.2016.00403</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Increased Motor-Impairing Effects of the Neuroactive Steroid Pregnanolone in Mice with Targeted Inactivation of the GABA<sub>A</sub> Receptor &#x03B3;2 Subunit in the Cerebellum</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Lepp&#x00E4;</surname> <given-names>Elli</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Linden</surname> <given-names>Anni-Maija</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/198924/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Aller</surname> <given-names>Maria I.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/370180/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wulff</surname> <given-names>Peer</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1142/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Vekovischeva</surname> <given-names>Olga</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Luscher</surname> <given-names>Bernhard</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1882/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>L&#x00FC;ddens</surname> <given-names>Hartmut</given-names></name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/23572/overview"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wisden</surname> <given-names>William</given-names></name>
<xref ref-type="aff" rid="aff6"><sup>6</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1137/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Korpi</surname> <given-names>Esa R.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="author-notes" rid="fn001"><sup>&#x002A;</sup></xref>
<uri xlink:href="http://loop.frontiersin.org/people/1891/overview"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Pharmacology, Faculty of Medicine, University of Helsinki</institution> <country>Helsinki, Finland</country></aff>
<aff id="aff2"><sup>2</sup><institution>Instituto de Neurociencias, Consejo Superior de Investigaciones Cient&#x00ED;ficas, Universidad Miguel Hern&#x00E1;ndez de Elche</institution> <country>San Juan de Alicante, Spain</country></aff>
<aff id="aff3"><sup>3</sup><institution>Institute of Physiology, University of Kiel</institution> <country>Kiel, Germany</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Biology, The Pennsylvania State University</institution> <country>University Park, PA, USA</country></aff>
<aff id="aff5"><sup>5</sup><institution>Department of Psychiatry and Psychotherapy, University Medical Center of the Johannes Gutenberg-University Mainz</institution> <country>Mainz, Germany</country></aff>
<aff id="aff6"><sup>6</sup><institution>Department of Life Sciences, Imperial College London</institution> <country>London, UK</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: <italic>A. Leslie Morrow, University of North Carolina at Chapel Hill, USA</italic></p></fn>
<fn fn-type="edited-by"><p>Reviewed by: <italic>Gregg E. Homanics, University of Pittsburgh, USA; Deborah Ann Finn, Oregon Health and Science University, USA</italic></p></fn>
<fn fn-type="corresp" id="fn001"><p>&#x002A;Correspondence: <italic>Esa R. Korpi, <email>esa.korpi@helsinki.fi</email></italic></p></fn>
<fn fn-type="other" id="fn002"><p>This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>27</day>
<month>10</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>7</volume>
<elocation-id>403</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>08</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>12</day>
<month>10</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2016 Lepp&#x00E4;, Linden, Aller, Wulff, Vekovischeva, Luscher, L&#x00FC;ddens, Wisden and Korpi.</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>Lepp&#x00E4;, Linden, Aller, Wulff, Vekovischeva, Luscher, L&#x00FC;ddens, Wisden and Korpi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract>
<p>Endogenous neurosteroids and neuroactive steroids have potent and widespread actions on the brain via inhibitory GABA<sub>A</sub> receptors. In recombinant receptors and genetic mouse models their actions depend on the &#x03B1;, &#x03B2;, and &#x03B4; subunits of the receptor, especially on those that form extrasynaptic GABA<sub>A</sub> receptors responsible for non-synaptic (tonic) inhibition, but they also act on synaptically enriched &#x03B3;2 subunit-containing receptors and even on &#x03B1;&#x03B2; binary receptors. Here we tested whether behavioral sensitivity to the neuroactive steroid agonist 5&#x03B2;-pregnan-3&#x03B1;-ol-20-one is altered in genetically engineered mouse models that have deficient GABA<sub>A</sub> receptor-mediated synaptic inhibition in selected neuronal populations. Mouse lines with the GABA<sub>A</sub> receptor &#x03B3;2 subunit gene selectively deleted either in parvalbumin-containing cells (including cerebellar Purkinje cells), cerebellar granule cells, or just in cerebellar Purkinje cells were trained on the accelerated rotating rod and then tested for motor impairment after cumulative intraperitoneal dosing of 5&#x03B2;-pregnan-3&#x03B1;-ol-20-one. Motor-impairing effects of 5&#x03B2;-pregnan-3&#x03B1;-ol-20-one were strongly increased in all three mouse models in which &#x03B3;2 subunit-dependent synaptic GABA<sub>A</sub> responses in cerebellar neurons were genetically abolished. Furthermore, rescue of postsynaptic GABA<sub>A</sub> receptors in Purkinje cells normalized the effect of the steroid. Anxiolytic/explorative effects of the steroid in elevated plus maze and light:dark exploration tests in mice with Purkinje cell &#x03B3;2 subunit inactivation were similar to those in control mice. The results suggest that, when the deletion of &#x03B3;2 subunit has removed synaptic GABA<sub>A</sub> receptors from the specific cerebellar neuronal populations, the effects of neuroactive steroids solely on extrasynaptic &#x03B1;&#x03B2; or &#x03B1;&#x03B2;&#x03B4; receptors lead to enhanced changes in the cerebellum-generated behavior.</p>
</abstract>
<kwd-group>
<kwd>extrasynaptic GABA<sub>A</sub> receptors</kwd>
<kwd>neurosteroids</kwd>
<kwd>cerebellum</kwd>
<kwd>motor performance</kwd>
<kwd>Purkinje cells</kwd>
</kwd-group>
<counts>
<fig-count count="5"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="59"/>
<page-count count="11"/>
<word-count count="0"/>
</counts>
</article-meta>
</front>
<body>
<sec><title>Introduction</title>
<p>Endogenous neurosteroids and synthetic neuroactive steroids are among the most potent and efficacious modulators of the brain&#x2019;s main ligand-gated inhibitory neurotransmitter receptor, the &#x03B3;-aminobutyric acid type A (GABA<sub>A</sub>) receptor, producing wide-ranging effects on behavior, including motor relaxation and impairment (<xref ref-type="bibr" rid="B10">Baulieu et al., 2001</xref>; <xref ref-type="bibr" rid="B12">Belelli et al., 2006</xref>). The concentrations of neurosteroids in the brain are increased in stress and by drugs, such as alcohol and antidepressants (<xref ref-type="bibr" rid="B8">Barbaccia, 2004</xref>). Endogenous concentrations of neurosteroids fluctuate during the ovarian cycle and in pregnancy, inducing changes in GABA<sub>A</sub> receptor subtype populations, particularly in those containing the &#x03B4; subunits (<xref ref-type="bibr" rid="B36">Maguire et al., 2005</xref>; <xref ref-type="bibr" rid="B48">Uusi-Oukari and Korpi, 2010</xref>; <xref ref-type="bibr" rid="B55">Wu et al., 2013</xref>; <xref ref-type="bibr" rid="B35">Mackenzie and Maguire, 2014</xref>), which may result in impaired regulation of mood in some patients (<xref ref-type="bibr" rid="B6">Backstrom et al., 2011</xref>, <xref ref-type="bibr" rid="B5">2014</xref>). Neurosteroid mechanisms have been implicated in acute liver failure and hepatic encephalopathy (<xref ref-type="bibr" rid="B2">Ahboucha et al., 2012</xref>). Furthermore, allopregnanolone, a metabolite of progesterone and one of the main endogenous GABAergic neurosteroids, promotes proliferation of neural progenitor cells <italic>in vitro</italic> via activation of GABA<sub>A</sub> receptors and, after a single dose, enhances neurogenesis in the hippocampal subgranular zone and in the dopaminergic substantia nigra <italic>pars compacta</italic> of adult transgenic model mice for Alzheimer&#x2019;s disease (<xref ref-type="bibr" rid="B51">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="B59">Zhang et al., 2015</xref>). However, chronic treatment with allopregnanolone accelerates Alzheimer&#x2019;s disease in several types of mouse models (<xref ref-type="bibr" rid="B14">Bengtsson et al., 2012</xref>, <xref ref-type="bibr" rid="B13">2013</xref>). There appears to be a need to better understand the mechanisms underlying neurosteroid sensitivity.</p>
<p>The mechanisms of neurosteroid sensitivity remain unclear. Neurosteroid actions can be mediated by all subtypes of GABA<sub>A</sub> receptors, with just &#x03B1; and &#x03B2; subunits giving full potency and efficacy (<xref ref-type="bibr" rid="B25">Hosie et al., 2006</xref>). The type of the &#x03B1; subunit mediates some of the variation noted in receptor properties, whereas the type of the &#x03B2; subunit has less influence. In recombinant receptors, inclusion of a &#x03B3;2 subunit has little effect on binding or efficacy compared to binary &#x03B1;&#x03B2; receptors, but the inclusion of the &#x03B4; subunit strongly increases the GABA-potentiating effects of neurosteroid agonists (<xref ref-type="bibr" rid="B11">Belelli et al., 2002</xref>; <xref ref-type="bibr" rid="B54">Wohlfarth et al., 2002</xref>). Neurosteroids affect both synaptic (mainly &#x03B3;2-GABA<sub>A</sub> dependent) and extrasynaptic (mainly &#x03B4;-GABA<sub>A</sub> dependent) inhibition in brain slices, but, in line with the increased efficacy of neurosteroids on &#x03B4; subunit-containing receptors, their behavioral and neurophysiological effects are strongly reduced when extrasynaptic GABAergic inhibition has been attenuated, e.g., in the GABA<sub>A</sub> receptor &#x03B4; subunit knockout mice (<xref ref-type="bibr" rid="B39">Mihalek et al., 1999</xref>; <xref ref-type="bibr" rid="B46">Spigelman et al., 2003</xref>; <xref ref-type="bibr" rid="B47">Stell et al., 2003</xref>). In the case of extrasynaptic GABA<sub>A</sub> receptors containing the &#x03B1;4 and &#x03B4; subunits, these mechanisms involve protein kinase C activation, and subsequent GABA<sub>A</sub> &#x03B1;4 subunit phosphorylation, increased membrane insertion of these receptors, leading to enhanced tonic conductance by prolonged exposure to neurosteroids (<xref ref-type="bibr" rid="B1">Abramian et al., 2014</xref>). Thus, whereas neurosteroid agonists affect both synaptic and extrasynaptic receptors, their behavioral effects seem to primarily depend on extrasynaptic receptors. It is evident that more information is needed on the effects of GABA<sub>A</sub> receptor subunit composition on neurosteroid sensitivity at the whole animal level.</p>
<p>In the present experiments, we genetically removed the &#x03B3;2 subunit in discrete neuronal populations. We used male mice to avoid estrus cycle-associated neurosteroid fluctuations. Using a simple cerebellum-related behavioral task on rotating rods, the mouse models enabled us to ascertain how the &#x03B3;2 subunit affects the sensitivity of the neuroactive steroid pregnanolone in cerebellar circuitry. The cerebellum was very suitable for these experiments, since the two main targets we used (Purkinje and granule cells) are known to express the &#x03B3;2 subunit and a limited number of other subunits [Purkinje cells &#x03B1;1, &#x03B2;2/3 and &#x03B3;2; granule cells &#x03B1;1/6, &#x03B2;2/3, &#x03B4; and &#x03B3;2 (<xref ref-type="bibr" rid="B52">Wisden et al., 1996</xref>)]. The contributions of extrasynaptic and synaptic GABA<sub>A</sub> receptors in mediating pregnanolone effects were further validated by transgenic re-introduction of the &#x03B3;2 subunit into Purkinje cells (PC-&#x03B3;2-swap mice) (<xref ref-type="bibr" rid="B56">Wulff et al., 2007</xref>; <xref ref-type="bibr" rid="B53">Wisden et al., 2009</xref>).</p>
</sec>
<sec id="s1" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec><title>Animals</title>
<p>All mice used for experiments were male. Parvalbumin (Pv)-neuron GABA<sub>A</sub> &#x03B3;2 subunit knockout mice (Pv-&#x0394;&#x03B3;2) and littermate control Pv-Cre mice were generated as described (<xref ref-type="bibr" rid="B57">Wulff et al., 2009a</xref>), by crossing Pv-Cre mice with &#x03B3;2I77 lox mice (<xref ref-type="bibr" rid="B20">Fuchs et al., 2007</xref>; <xref ref-type="bibr" rid="B56">Wulff et al., 2007</xref>). Pv-&#x0394;&#x03B3;2 mice were important for the study, since cerebellar Purkinje cells and molecular layer interneurons are positive for parvalbumin (<xref ref-type="bibr" rid="B32">Leppa et al., 2011</xref>), and thus lose synaptic inhibition. Cerebellar granule cell (Gr) GABA<sub>A</sub> &#x03B3;2 subunit knockout (Gr-&#x0394;&#x03B3;2) homozygous (-/-), heterozygous (+/-) and wild-type (+/+) littermate mice were generated by crossing &#x03B1;6-Cre mice [<underline>B6.129P2-</underline><italic><underline>Gabra6<sup>tm2(cre)Wwis</sup></underline></italic><underline>/Mmucd</underline> mouse mutant resource stock MMRRC:015968-UCD (<xref ref-type="bibr" rid="B3">Aller et al., 2003</xref>)] with a mouse line containing a &#x03B3;2 gene flanked by lox P sites [Jax lab STOCK No. 016830, <italic>Gabrg2</italic><sup>tm2Lusc</sup>/J, also known as f&#x03B3;2 mice (<xref ref-type="bibr" rid="B44">Schweizer et al., 2003</xref>)]. Gr-&#x0394;&#x03B3;2 mice were used to study the effect of &#x03B3;2 subunit deficiency in only one major cerebellar neuron population. Cerebellar Purkinje cell (PC) GABA<sub>A</sub> &#x03B3;2 subunit knockout mice (PC-&#x0394;&#x03B3;2) and littermate control &#x03B3;2I77lox mice were generated as described (<xref ref-type="bibr" rid="B56">Wulff et al., 2007</xref>), by crossing &#x03B3;2I77lox mice with L7-Cre mice (<xref ref-type="bibr" rid="B9">Barski et al., 2000</xref>; <xref ref-type="bibr" rid="B56">Wulff et al., 2007</xref>). The &#x03B3;2I77lox mice are available at JAX labs, stock STOCK 021197 <italic>Gabrg2</italic><sup>tm1Wul</sup>/J, and have loxP sites surrounding exon 4 of the &#x03B3;2 subunit gene (<xref ref-type="bibr" rid="B56">Wulff et al., 2007</xref>). The &#x03B3;2I77lox mice have the GABA<sub>A</sub> receptor &#x03B3;2 subunit F77 residue point-mutated to encode I77, causing an inability of the &#x03B3;2 subunit-dependent benzodiazepine binding site to mediate pharmacological effects of the sedative-hypnotic zolpidem and the &#x03B2;-carboline convulsant 3-carbomethoxy-4-ethyl-6,7-dimethoxy-&#x03B2;-carboline (<xref ref-type="bibr" rid="B17">Cope et al., 2005</xref>; <xref ref-type="bibr" rid="B33">Leppa et al., 2005</xref>) and to bind with high affinity the universal benzodiazepine site ligand [<sup>3</sup>H]Ro 15-4513 (<xref ref-type="bibr" rid="B32">Leppa et al., 2011</xref>; <xref ref-type="bibr" rid="B34">Linden et al., 2011</xref>) (see <bold>Figure <xref ref-type="fig" rid="F3">3C</xref></bold>). In other aspects the &#x03B3;2I77 subunit-containing GABA<sub>A</sub> receptors function normally (<xref ref-type="bibr" rid="B17">Cope et al., 2005</xref>). PC GABA<sub>A</sub> &#x03B3;2 subunit swap mice (PC-&#x03B3;2-swap) were generated by expressing the wildtype &#x03B3;2 subunit under the control of Purkinje-cell specific L7-promoter to restore wildtype &#x03B3;2 expression in PCs following the specific inactivation of &#x03B3;2 I77 subunit in these cells (in PC-&#x0394;&#x03B3;2 mice). The PC-&#x03B3;2-swap mice have been previously used to selectively restore zolpidem sensitivity in Purkinje cells to study how selective inhibition of PCs by zolpidem affects motor performance (<xref ref-type="bibr" rid="B56">Wulff et al., 2007</xref>).</p>
<p>For all the conditional mouse crosses, all experiments were performed on mice homozygous for the conditional &#x03B3;2 allele and hemizygous for the Cre transgenes; Cre-negative mice served as the littermate controls. The mice were 4&#x2013;10 months old when used. Weights at the rotarod testing: Pv-&#x0394;&#x03B3;2 mice and their Pv-Cre/&#x03B3;2I77 controls 22 &#x00B1; 3 (<italic>n</italic> = 7) and 25 &#x00B1; 2 (8) g (mean &#x00B1; SD), respectively; Gr-&#x0394;&#x03B3;2+/+, +/-, and -/- mice 32 &#x00B1; 4 (5), 31 &#x00B1; 2 (10), and 29 &#x00B1; 1 (6) g, respectively; PC-&#x0394;&#x03B3;2, &#x03B3;2I77lox and PC-&#x03B3;2-swap mice 25 &#x00B1; 4 (5), 25 &#x00B1; 6 (10) and 24 &#x00B1; 2 (6) g, respectively. The animals were housed (1&#x2013;5 per cage) in transparent polypropylene Makrolon cages with standard rodent pellets (Harlan Teklad Global Diet, Bicester, UK) and tap water <italic>ad lib</italic>. Lights were on from 7 a.m. to 7 p.m.</p>
<p>All behavioral animal experiments were carried out with the permissions (ESLH-2004-01605/Ym-23 and ESLH-2006-09005/Ym-23) of the State Provincial Government of Southern Finland, the governing body that oversaw animal ethics for the University of Helsinki. All efforts were made to minimize the number and suffering of animals. About 1 week after behavioral tests, the animals were strongly sedated with CO<sub>2</sub>, decapitated, and brains dissected out for further analyses.</p>
</sec>
<sec><title>Motor Tests</title>
<p>To investigate the motor coordination capabilities of each mouse line rotarod tests were performed (<xref ref-type="bibr" rid="B30">Korpi et al., 1999</xref>). The mice were trained during 7 days (4&#x2013;6 trials per day) to stay on a rotating rod (diameter 4 cm, Rotamex 4/8, Columbus Instruments, Columbus, OH, USA) for 180 s, with the rotation speed being linearly accelerated from 5 to 30 rpm. Due to the impairment in motor performance of Pv-&#x0394;&#x03B3;2 mice, a lower speed of 5 to 20 rpm was used in the training of these and their littermate control mice. The latency to fall from the rod in each trial was recorded and a daily average of 4&#x2013;6 trials was calculated for each animal.</p>
<p>To study the sensitivities of the mouse lines to neurosteroids a synthetic neuroactive steroid 5&#x03B2;-pregnan-3&#x03B1;-ol-20-one (pregnanolone, Sigma&#x2013;Aldrich Chemical Company, St. Louis, MO, USA) was used. Well-trained animals were injected with vehicle or pregnanolone at 30 min intervals, 15 min before each single-trial rotarod testing. Drug dosing was cumulative, in order to reduce the number of tested animals (vehicle+10+10+10 mg pregnanolone/kg, for the total dose of 30 mg/kg). Cumulative dosing has been used successfully in previous dose-response studies for other drugs (<xref ref-type="bibr" rid="B18">Cope et al., 2004</xref>; <xref ref-type="bibr" rid="B56">Wulff et al., 2007</xref>). Pregnanolone was dissolved overnight in cremophor (Cremophor EL, Sigma) and brought to concentration with physiological saline (final concentration 30% cremophor, which was used without pregnanolone as a vehicle control). Pregnanolone and vehicle solutions were injected i.p. in a volume of 10 ml/kg body weight.</p>
</sec>
<sec><title>Tests for Anxiolytic and Explorative Activity</title>
<p>To compare the PC-mouse lines in the effects of pregnanolone on the level of anxiety and explorative activity, we used a batch of mice that was na&#x00EF;ve to behavioral tests in elevated plus-maze test and light:dark exploration test, as described in (<xref ref-type="bibr" rid="B43">Saarelainen et al., 2008</xref>; <xref ref-type="bibr" rid="B32">Leppa et al., 2011</xref>), with 1 week washout between the tests.</p>
<p>The elevated plus-maze test was performed on the apparatus made of gray plastic and elevated to 50 cm from the floor level. It consisted of a central platform (5 cm &#x00D7; 5 cm), from which two open arms (5 cm &#x00D7; 40 cm with a 0.7 cm ledge) and two enclosed arms (5 cm &#x00D7; 40 cm &#x00D7; 20 cm) extended. The mice were placed individually on the central platform facing an open arm and allowed free exploration of the maze for 5 min with their behavior being recorded using a video tracking system with a CCD video camera above the plus maze. This was done 15 min after the injection of vehicle or pregnanolone (10 mg/kg, i.p.), which was done in a balanced order. The position and movements of the center of the animal&#x2019;s surface area were analyzed automatically using EthoVision software Color-Pro 3.0 software (Noldus Information Technology, Wageningen, Netherlands). The central area was extended to include the first 2 cm of each arm. An arm entry was recorded when the center of the mouse entered the distal part of the arm. This corresponds to the definition of an arm entry with all four legs on the arm. During 5-min testing periods the time spent on the open arms, the number of entries into the arms, and the total distance traveled in the maze were recorded and analyzed by EthoVision. The plus maze was carefully cleaned with water-moistened paper towel and dried after each mouse, thus avoiding any aversive smells to carry over to the next mouse. The mice were returned to their home cage when all mice from the same cage were tested.</p>
<p>The light:dark test (<xref ref-type="bibr" rid="B43">Saarelainen et al., 2008</xref>) was started by placing a mouse in the lit compartment of two-compartment box (47 cm &#x00D7; 29 cm &#x00D7; 35 cm) divided into one dark (16 cm &#x00D7; 29 cm) and one lit (31 cm &#x00D7; 29 cm; about 450 lux) area with open door (7 cm &#x00D7; 8 cm) between them. This was done 15 min after the injection of vehicle or pregnanolone. In this test, we used a slightly lower dose (7 mg/kg, i.p.) than in the elevated plus-maze test to ensure that any sensitivity differences in anxiolytic effects would be detectable. During 5-min testing periods the time spent in the lit compartment, the number of crossings between compartments and the distance traveled in the lit compartment were recorded and analyzed by EthoVision. The test-box was cleaned and dried after each mouse as was done in the elevated plus-maze test, and the mice were returned to their home cage when all mice from the same cage were tested.</p>
</sec>
<sec><title>Ligand Autoradiography</title>
<p>Autoradiography of mouse brain horizontal 14-&#x03BC;m-thick cryostat sections was performed as described (<xref ref-type="bibr" rid="B31">Korpi and Luddens, 1997</xref>; <xref ref-type="bibr" rid="B37">Makela et al., 1997</xref>). For [<sup>3</sup>H]Ro 15-4513 autoradiography the sections were incubated at 4&#x00B0;C for 60 min with 15 nM [<sup>3</sup>H]Ro 15-4513 (Perkin-Elmer Life Sciences Inc., Waltham, MA, USA). Non-specific binding was determined with 10 &#x03BC;M Ro 15-1788 (flumazenil, Tocris Bioscience, MS, USA). For [<sup>35</sup>S]TBPS autoradiography the sections were incubated with 6 nM [<sup>35</sup>S]-<italic>t</italic>-butylbicyclophosphorothionate ([<sup>35</sup>S]TBPS, Perkin-Elmer) in the incubation buffer (50 mM Tris-HCl, 120 mM NaCl, pH 7.4) at room temperature for 90 min. Non-specific binding was determined with 100 &#x03BC;M picrotoxinin (Sigma). After the washing and drying, the sections were exposed to Kodak Biomax MR film for 1&#x2013;24 weeks with <sup>3</sup>H (for [<sup>3</sup>H]Ro 15-4513) or <sup>14</sup>C (for [<sup>35</sup>S]TBPS) radioactivity standards (Amersham Biosciences corp., Piscataway, NJ, USA). Binding densities in the multiple locations of the granule cell and/or molecular layers of the cerebellum were quantitated with MCID M5-imaging software (Imaging Research Inc., St. Catherines Ontario, ON, Canada) and converted to radioactivity values on the basis of the simultaneously exposed standards. Non-specific binding was subtracted from all values. Importantly, in [<sup>3</sup>H]Ro 15-4513 autoradiography, the radioligand concentration (15 nM) was about three times higher than the dissociation constant Kd of the binding (<xref ref-type="bibr" rid="B45">Sieghart, 1995</xref>). Thus, the images mainly reflected the number of binding sites.</p>
</sec>
<sec><title>Ligand Binding to Recombinant Receptors</title>
<p>Human embryonic kidney cells [HEK 293 cells; German collection of microorganisms and cell cultures (DSMZ), Braunschweig, Germany] were grown to &#x003C;50% confluency on 15-cm tissue plates in 20 ml DMEM supplemented with 10% heat-inactivated fetal calf serum, 5 mM glutamine as well as penicillin and streptomycin. Transfection was carried out with a Ca<sup>2+</sup>-phosphate precipitation method essentially as described (<xref ref-type="bibr" rid="B27">Jordan et al., 1996</xref>). Briefly, plasmids were diluted in 1 ml/ plate of 0.3125 M CaCl<sub>2</sub> in H<sub>2</sub>O. One ml/ plate of 2x HBS (274 mM NaCl; 1.5 mM Na<sub>2</sub>HPO<sub>4</sub>; 54.6 mM HEPES/NaOH; pH 7.0) was added to the DNA and incubated for 90 s. Two ml of the mixture were pipetted into 15-cm plates that were incubated for 18&#x2013;24 h before the transfection medium was replaced by fresh medium. Double and triple combinations of rat GABA<sub>A</sub> receptor cDNAs in eukaryotic expression vectors (<xref ref-type="bibr" rid="B42">Pritchett and Seeburg, 1990</xref>) of the &#x03B1;1, &#x03B2;3, &#x03B3;2S, and &#x03B4; subunits were employed. Final concentrations (&#x03BC;g vector DNA per 15 cm tissue culture plate) were: &#x03B1;1, 2.5; &#x03B2;3, 0.5; &#x03B3;2S, 0.375, and &#x03B4;, 2.5.</p>
<p>Cell membranes were prepared as described (<xref ref-type="bibr" rid="B31">Korpi and Luddens, 1997</xref>). Resuspended crude cell membranes (50&#x2013;200 &#x03BC;g protein per tube) were incubated in a final volume of 0.5 ml of 50 mM Tris/citrate buffer supplemented with 0.2 M NaCl, pH 7.3, with 3 nM [<sup>3</sup>H]EBOB ([<sup>3</sup>H]ethynylbicycloorthobenzoate, NEN) with or without pregnanolone in the presence or absence of GABA. Pregnanolone was made up in DMSO at a stock of 10 mM in DMSO. GABA was diluted from a 100 mM solution in H<sub>2</sub>O. Binding assay procedure was performed as described earlier (<xref ref-type="bibr" rid="B31">Korpi and Luddens, 1997</xref>).</p>
</sec>
<sec><title>Statistical Analyses</title>
<p>Statistical tests were performed with SPSS Software (SPSS 12.0.1, SPSS Inc., Chicago, IL, USA) or GraphPad Prism software (Prism 6.0, GraphPad Software Inc., San Diego, California, USA). Treatment groups and mouse lines were compared with either repeated measures ANOVA, one-way ANOVA or two-way ANOVA followed by Newman&#x2013;Keuls <italic>post hoc</italic> test or Dunnett&#x2019;s test. In all statistical tests the level of significance was set at <italic>P</italic> &#x003C; 0.05.</p>
</sec>
</sec>
<sec><title>Results</title>
<p>A mouse line [Pv-&#x0394;&#x03B3;2, (<xref ref-type="bibr" rid="B57">Wulff et al., 2009a</xref>)] with inactivated synaptic GABA<sub>A</sub> receptor-mediated inhibition of Pv-expressing neurons exhibited a high sensitivity to the exogenous neuroactive steroid 5&#x03B2;-pregnan-3&#x03B1;-ol-20-one (pregnanolone; <bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>). Naive Pv-&#x0394;&#x03B3;2 mice exhibited ataxia, but they could learn to stay on a rotating rod that accelerated from 5 to 20 rpms (<bold>Figure <xref ref-type="fig" rid="F1">1A</xref></bold>). However, when these mice were challenged by cumulative dosing of pregnanolone they quickly fell down from the rod, while the control littermates were only slightly affected (<bold>Figure <xref ref-type="fig" rid="F1">1B</xref></bold>, drug treatment &#x00D7; genotype interaction <italic>F</italic><sub>3,53</sub> = 5.33, <italic>P</italic> &#x003C; 0.01). Electrophysiology of the Pv-expressing hippocampal interneurons in the genetically engineered mice indicated abolition of synaptic GABA<sub>A</sub> receptor-mediated inhibitory postsynaptic currents (IPSCs) (<xref ref-type="bibr" rid="B57">Wulff et al., 2009a</xref>). Pv-expression is widespread in the brain, including the cerebellar PCs (<xref ref-type="bibr" rid="B38">Meyer et al., 2002</xref>; <xref ref-type="bibr" rid="B32">Leppa et al., 2011</xref>; <xref ref-type="bibr" rid="B28">Kaiser et al., 2015</xref>). Thus, it seemed possible that neurosteroids can induce strong neuronal effects especially in the absence of their target receptors from a set of synapses.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption><p><bold>Neurosteroid sensitivity of Pv-&#x0394;&#x03B3;2 mice with targeted inactivation of GABA<sub>A</sub> receptor &#x03B3;2 subunit gene in parvalbumin-expressing neurons. (A)</bold> Learning the rotarod performance. The rotarod was accelerated from 5 to 20 rpm during 180 s. Data for &#x03B3;2I77lox control (<italic>n</italic> = 8) and Pv-&#x0394;&#x03B3;2 (<italic>n</italic> = 7) mice are presented as daily means of 6 trials &#x00B1; SEM. <sup>#</sup><italic>P</italic> &#x003C; 0.05 for the significance of the difference between the mouse lines on training days 1 and 2 (repeated measures ANOVA and Newman&#x2013;Keuls <italic>post hoc</italic> tests). <bold>(B)</bold> Effects of pregnanolone on motor performance. Pregnanolone was administered in cumulative doses (10+10+10 mg/kg i.p., total 30 mg/kg) to the same animals and the performance tested as in panel <bold>(A)</bold>. One-way ANOVA and Newman&#x2013;Keuls <italic>post hoc</italic> tests: <sup>##</sup><italic>P</italic> &#x003C; 0.01, <sup>###</sup><italic>P</italic> &#x003C; 0.001 for the significance of the difference between the mouse lines, <sup>&#x2217;</sup><italic>P</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>P</italic> &#x003C; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>P</italic> &#x003C; 0.001 for the significance of the difference from vehicle injection within the Pv-&#x0394;&#x03B3;2 line. Data are presented as means &#x00B1; SEM.</p></caption>
<graphic xlink:href="fphar-07-00403-g001.tif"/>
</fig>
<p>Since Pv-expressing neurons exist at a low and diffuse level in most areas of the central nervous system, including motor neurons of the brain stem and spinal cord, and because they have abundant connections between each other and to principal neurons throughout the brain, interpretation of the effect of global Pv-cell-specific elimination of synaptic inhibition is complicated. Thus, we next wanted to use a mouse model with a more restricted ablation of synaptic inhibition. We produced cerebellar granule cell-selective GABA<sub>A</sub> receptor &#x03B3;2 subunit knockout mice (Gr-&#x0394;&#x03B3;2) by cross-breeding &#x03B1;6-Cre (<xref ref-type="bibr" rid="B3">Aller et al., 2003</xref>) and floxed &#x03B3;2 mice (<xref ref-type="bibr" rid="B44">Schweizer et al., 2003</xref>). Autoradiography of cerebellar sections showed that in the granule cell layer, the Gr-&#x0394;&#x03B3;2 knockouts lack the &#x03B3;2 subunit-dependent high-affinity labeling of the benzodiazepine binding sites, but contain normal labeling of integral ionophore sites of GABA<sub>A</sub> receptors (<bold>Figure <xref ref-type="fig" rid="F2">2A</xref></bold>). This is consistent with the loss of &#x03B3;2 subunit-containing receptors at synapses between GABAergic Golgi interneurons and granule cells. In spite of these deficits in synaptic receptors, the Gr-&#x0394;&#x03B3;2 mice learnt normally to run on a rotarod and did not show obvious motor deficits (<bold>Figure <xref ref-type="fig" rid="F2">2B</xref></bold>). Interestingly, these mice showed a significant increase in pregnanolone sensitivity as compared to littermate controls and heterozygous knockouts (<bold>Figure <xref ref-type="fig" rid="F2">2C</xref></bold>; drug treatment &#x00D7; genotype interaction <italic>F</italic><sub>6,72</sub> = 2.87, <italic>P</italic> &#x003C; 0.05).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption><p><bold>Neurosteroid sensitivity of Gr-&#x0394;&#x03B3;2 mice with targeted inactivation of GABA<sub>A</sub> receptor &#x03B3;2 subunit gene in the cerebellar granule cells. (A)</bold> Ligand binding sites in horizontal brain sections from Gr-&#x0394;&#x03B3;2 mice with the wildtype &#x03B3;2 subunit background. [<sup>3</sup>H]Ro 15-4513 labels the &#x03B3;2 subunit-dependent flumazenil-sensitive benzodiazepine sites, which are deficient in the cerebellar granule cell layer of the genetically engineered mice, but not in the molecular layer (as shown in the bar graph). [<sup>35</sup>S]TBPS labels the picrotoxin-sensitive ionophore sites of the GABA<sub>A</sub> receptor, and this labeling is intact in the cerebellum of the genetically engineered mice, suggesting normal amounts of &#x03B1; and &#x03B2; subunit expression. <bold>(B)</bold> Rotarod learning. The rotarod was accelerated from 5 to 30 rpm during 180 s. Data for wild-type +/+ (<italic>n</italic> = 5), heterozygous +/- (<italic>n</italic> = 10) and Gr-&#x0394;&#x03B3;2 knockout -/- (<italic>n</italic> = 6) mice are presented as daily means of 6 trials &#x00B1; SEM. There were no significant differences between mouse lines. <bold>(C)</bold> Effects of pregnanolone on rotarod performance. Pregnanolone was administered in cumulative doses (10+10+10 mg/kg i.p., total 30 mg/kg) to the same animals, and the performance tested, as in panel <bold>(B)</bold>. ANOVA followed by Newman&#x2013;Keuls <italic>post hoc</italic> tests: <sup>&#x000A4;</sup><italic>P</italic> &#x003C; 0.05 for the significance of the difference of +/+ and +/- mice from the -/- mice. <sup>&#x2217;</sup><italic>P</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>P</italic> &#x003C; 0.001 for the significance of the difference compared to vehicle within lines. Data are presented as means &#x00B1; SEM.</p></caption>
<graphic xlink:href="fphar-07-00403-g002.tif"/>
</fig>
<p>Our third mouse model focused on manipulating inhibitory synaptic input to cerebellar Purkinje cells. We performed motor tests in male PC-&#x0394;&#x03B3;2 mice (<xref ref-type="bibr" rid="B56">Wulff et al., 2007</xref>). These mice lack the spontaneous IPSCs of Purkinje neurons (<xref ref-type="bibr" rid="B56">Wulff et al., 2007</xref>), but they exhibited only a minor transient motor impairment during the 1st day of rotarod training. The motor-impairing effect of pregnanolone on rotarod performance was clearly enhanced in PC-&#x0394;&#x03B3;2 mice as compared to littermates (<bold>Figures <xref ref-type="fig" rid="F3">3A,B</xref></bold>; drug treatment &#x00D7; genotype interaction, <italic>F</italic><sub>6,69</sub> = 2.96, <italic>P</italic> = 0.05). Importantly, the re-introduction of wildtype &#x03B3;2 subunits to PCs, as evidenced by autoradiographic (<bold>Figure <xref ref-type="fig" rid="F3">3C</xref></bold>) and electrophysiological experiments (<xref ref-type="bibr" rid="B56">Wulff et al., 2007</xref>), fully abolished the increased pregnanolone sensitivity (<bold>Figure <xref ref-type="fig" rid="F3">3B</xref></bold>; <italic>P</italic> > 0.05 for the difference between PC-&#x03B3;2-swap and &#x03B3;2I77lox lines). These results finally implicate PCs as targets of pregnanolone in the cerebellar cortex resulting in impaired motor coordination.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption><p><bold>Neurosteroid sensitivity of PC-&#x0394;&#x03B3;2 mice with targeted inactivation of GABA<sub>A</sub> receptor &#x03B3;2 subunit gene in the cerebellar Purkinje neurons. (A)</bold> Effects of pregnanolone on motor performance. Pregnanolone was administered in cumulative doses (10+10+10 mg/kg i.p., total 30 mg/kg) to the control &#x03B3;2I77lox (<italic>n</italic> = 5) and PC-&#x0394;&#x03B3;2 (<italic>n</italic> = 5) mice, and the performance tested on accelerating rotarod (from 5 to 30 rpm) during 180 s. ANOVA followed by Newman&#x2013;Keuls <italic>post hoc</italic> tests: <sup>##</sup><italic>P</italic> &#x003C; 0.01 for the significance of the difference between the mouse lines, <sup>&#x2217;</sup><italic>P</italic> &#x003C; 0.05 for the significance of the difference compared to vehicle within the PC-&#x0394;&#x03B3;2 line. Data are presented as means &#x00B1; SEM. <bold>(B)</bold> Effects of wildtype &#x03B3;2 subunit rescue to the Purkinje neurons in PC-&#x03B3;2-swap mice on pregnanolone sensitivity. Drug administration and testing of &#x03B3;2I77lox (<italic>n</italic> = 10), PC-&#x0394;&#x03B3;2 (<italic>n</italic> = 5) and PC-&#x03B3;2-swap (<italic>n</italic> = 6) mice were carried out as in panel <bold>(A)</bold>. ANOVA followed by Newman&#x2013;Keuls <italic>post hoc</italic> tests: <sup>#</sup><italic>P</italic> &#x003C; 0.05, <sup>##</sup><italic>P</italic> &#x003C; 0.01 for the significance of the difference between PC-&#x0394;&#x03B3;2 and &#x03B3;2I77lox mice. &#x000A4;<italic>P</italic> &#x003C; 0.05 for the significance of the difference between PC-&#x0394;&#x03B3;2 and PC-&#x03B3;2-swap mouse lines. <sup>&#x2217;</sup><italic>P</italic> &#x003C; 0.05, <sup>&#x2217;&#x2217;</sup><italic>P</italic> &#x003C; 0.01, <sup>&#x2217;&#x2217;&#x2217;</sup><italic>P</italic> &#x003C; 0.001 for the significance of the difference compared to vehicle injection within the mouse lines. Data are presented as means &#x00B1; SEM. <bold>(C)</bold> Representative images of &#x03B3;2 subunit-dependent [<sup>3</sup>H]Ro 15-4513 binding in normal wildtype C57BL/6J, &#x03B3;2I77lox, PC-&#x0394;&#x03B3;2 and PC-&#x03B3;2-swap mouse horizontal brain sections, demonstrating a clear rescue of molecular layer binding in PC-&#x03B3;2-swap mice. Please, note the very low binding in the forebrain regions in the brains with &#x03B3;2I77lox background as compared to the wildtype brain. Representative cerebellar images of GABA<sub>A</sub> receptor ionophore binding sites labeled with [<sup>35</sup>S]TBPS show unchanged binding in genetically engineered mice.</p></caption>
<graphic xlink:href="fphar-07-00403-g003.tif"/>
</fig>
<p>To test whether PC-&#x0394;&#x03B3;2 mice show enhanced sensitivity in other than motor coordination tests, doses of pregnanolone that are not strongly motor impairing (7 and 10 mg/kg) were tested for possible anxiolytic/exploration-increasing effects in the elevated plus maze and light:dark exploration tests, but the results were essentially similar in &#x03B3;2I77lox and PC-&#x0394;&#x03B3;2 mice (<bold>Figure <xref ref-type="fig" rid="F4">4</xref></bold>), thus showing no baseline differences in any measures, nor any significant mouse line or interaction effects in the ANOVA. Pregnanolone treatment induced an anxiolytic-like effect that was similar in both mouse lines. It significantly increased the time on the open arms (<italic>F</italic><sub>1,29</sub> = 11.8, <italic>P</italic> = 0.002) and the proportion of open arm entries (<italic>F</italic><sub>1,29</sub> = 12.2, <italic>P</italic> = 0.0015) and reduced the distance moved (<italic>F</italic><sub>1,29</sub> = 7.6, <italic>P</italic> = 0.01) in the plus maze test, and it tended to increase the time in the lit compartment (<italic>F</italic><sub>1,31</sub> = 3.44, <italic>P</italic> = 0.07), increased number of crossings between the compartments (<italic>F</italic><sub>1,31</sub> = 7.07, <italic>P</italic> = 0.012) and increased distance traveled in the lit compartment (<italic>F</italic><sub>1,31</sub> = 7.34, <italic>P</italic> = 0.010) in the light:dark test. Furthermore, PC-&#x0394;&#x03B3;2 mice showed no reduction in locomotor activity in these tests as compared to controls.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption><p><bold>Effects of pregnanolone on PC-&#x0394;&#x03B3;2 mice with targeted inactivation of GABA<sub>A</sub> receptor &#x03B3;2 subunit gene in the cerebellar Purkinje neurons in tests for anxiety and exploration.</bold> The &#x03B3;2I77lox and PC-&#x0394;&#x03B3;2 mice were treated with vehicle or pregnanolone (at doses indicated below the bars, in mg/kg i.p.) and 15 min later tested in the elevated plus maze <bold>(A)</bold> and light:dark exploration <bold>(B)</bold> tests. The results (means &#x00B1; SEM, <italic>n</italic> = 7&#x2013;9 per group) show no differences between mouse lines (two-way ANOVA, <italic>P</italic> > 0.1), but significant effects by the treatment in both tests for all measures (<italic>P</italic> &#x003C; 0.013), except for the % time in the lit area (<italic>P</italic> = 0.07).</p></caption>
<graphic xlink:href="fphar-07-00403-g004.tif"/>
</fig>
<p>Purkinje cells express especially the &#x03B1;1 subunit-containing GABA<sub>A</sub> receptors (<xref ref-type="bibr" rid="B52">Wisden et al., 1996</xref>). Therefore, we used recombinant GABA<sub>A</sub> receptors to assess whether different &#x03B1;1 subunit-containing receptor subtypes are affected by the presence of pregnanolone. In the absence of GABA, among &#x03B1;1&#x03B2;3, &#x03B1;1&#x03B2;3&#x03B3;2, and &#x03B1;1&#x03B2;3&#x03B4; receptors only the &#x03B4; subunit-containing receptor &#x03B1;1&#x03B2;3&#x03B4; responded to increasing concentrations of pregnanolone with increased binding of [<sup>3</sup>H]EBOB (<bold>Figure <xref ref-type="fig" rid="F5">5</xref></bold>). At 1 &#x03BC;M GABA, pregnanolone reduced [<sup>3</sup>H]EBOB binding to &#x03B1;1&#x03B2;3 and &#x03B1;1&#x03B2;3&#x03B3;2 receptors (<bold>Figure <xref ref-type="fig" rid="F5">5</xref></bold>), but had no effects on &#x03B1;1&#x03B2;3&#x03B4;. At the highest GABA concentration tested (10 &#x03BC;M), high nanomolar pregnanolone reduced the binding to &#x03B1;1&#x03B2;3&#x03B4; receptors but had no more effects on the already low binding to &#x03B1;1&#x03B2;3 and &#x03B1;1&#x03B2;3&#x03B3;2 receptors. These data suggest that also in a biochemical assay of recombinant GABA<sub>A</sub> receptor function, the &#x03B4; subunit-containing receptors respond strongly to the presence of pregnanolone. More importantly, the &#x03B1;1&#x03B2;3 receptors that do not have the address to go to synapses are as strongly affected as &#x03B1;1&#x03B2;3&#x03B3;2 receptors by pregnanolone.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption><p><bold>Effects of pregnanolone on GABA<sub>A</sub> receptor subtypes in the presence and absence of GABA.</bold> GABA<sub>A</sub> receptors of the given subunit combinations were transiently expressed in HEK 293 cells and incubated with 3 nM [<sup>3</sup>H]EBOB in the presence and absence of GABA and increasing concentrations of pregnanolone, as indicated. Data are presented as the means &#x00B1; SEM, <italic>n</italic> = 3&#x2013;5. All data were normalized to the [<sup>3</sup>H]EBOB binding with setting 0-&#x03BC;M GABA + 0-&#x03BC;M pregnanolone to 100%.</p></caption>
<graphic xlink:href="fphar-07-00403-g005.tif"/>
</fig>
</sec>
<sec><title>Discussion</title>
<p>Neurosteroids are potent modulators of brain GABA<sub>A</sub> receptors and their significance to various behavioral states is under active investigation. The level of endogenous neurosteroids is thought to influence neuronal excitability, e.g., in catamenial epilepsy, premenstrual syndrome and migraine as well as depression (<xref ref-type="bibr" rid="B49">van Broekhoven and Verkes, 2003</xref>; <xref ref-type="bibr" rid="B55">Wu et al., 2013</xref>; <xref ref-type="bibr" rid="B5">Backstrom et al., 2014</xref>). Neurosteroid mechanisms seem to be important also in liver failure and hepatic encephalopathy (<xref ref-type="bibr" rid="B2">Ahboucha et al., 2012</xref>) and in Alzheimer&#x2019;s disease models (<xref ref-type="bibr" rid="B51">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="B14">Bengtsson et al., 2012</xref>, <xref ref-type="bibr" rid="B13">2013</xref>; <xref ref-type="bibr" rid="B59">Zhang et al., 2015</xref>). Using several GABA<sub>A</sub> receptor genetically engineered mouse models we show here that the neuroactive steroid agonist pregnanolone can strongly modulate learned motor performance when the balance of non-synaptic (extrasynaptic) and synaptic GABA<sub>A</sub> receptors was altered in a set of neuronal populations with inactivated &#x03B3;2 subunits. Previous findings on &#x03B1;4 and &#x03B4; subunit-containing receptors in hippocampal areas indicate that neurosteroid agonists powerfully facilitate tonic inhibition mediated by GABA<sub>A</sub> receptors (<xref ref-type="bibr" rid="B15">Carver et al., 2014</xref>). These results, together with the reduced sensitivity of neurosteroids in GABA<sub>A</sub> receptor &#x03B4; knockout mice (<xref ref-type="bibr" rid="B39">Mihalek et al., 1999</xref>; <xref ref-type="bibr" rid="B47">Stell et al., 2003</xref>), strongly indicate that the extrasynaptic GABA<sub>A</sub> receptors are the preferential targets of neurosteroids. Importantly, in the present study these preferential effects could be detected in mice with impaired synaptic inhibition only in a single population of neurons after inactivation of the &#x03B3;2 subunit that is essential for synaptic targeting of GABA<sub>A</sub> receptors (<xref ref-type="bibr" rid="B19">Crestani et al., 1999</xref>), without any general enhancement of &#x03B4; subunit-containing GABA<sub>A</sub> receptors. It should anyway be kept in mind that compensatory changes may take place after inactivation of &#x03B3;2 subunits, although the &#x03B4; subunit is not known to be expressed in the cerebellar PCs (<xref ref-type="bibr" rid="B52">Wisden et al., 1996</xref>) and global &#x03B3;2 inactivation cannot be efficiently compensated in mice (<xref ref-type="bibr" rid="B21">Gunther et al., 1995</xref>).</p>
<p>The modulation of binding of the GABA<sub>A</sub> receptor ionophore ligand [<sup>3</sup>H]EBOB was different in the &#x03B4; subunit-containing receptors than in binary &#x03B1;&#x03B2; or &#x03B3;2 subunit-containing receptors (<bold>Figure <xref ref-type="fig" rid="F5">5</xref></bold>), again indicating a possibility that &#x03B4; subunit-containing GABA<sub>A</sub> receptors have features that make neurosteroid effects in them more potent or efficient. Further study is needed to understand the molecular mechanisms how the general neurosteroid binding sites on &#x03B1; subunits (<xref ref-type="bibr" rid="B24">Hosie et al., 2009</xref>) are transducing the signal to the ionophore structure in the &#x03B4; subunit-containing receptors differently from &#x03B4; subunit-absent receptors.</p>
<p>The alteration of balance between synaptic and extrasynaptic inhibition might be also operative in the regulation of other neuronal pathways that mediate more subtle behaviors such as emotions and irritability, that are known to be associated with altered endogenous neurosteroid metabolism and GABAergic inhibition (<xref ref-type="bibr" rid="B4">Backstrom et al., 2003</xref>). In the present study the anxiolytic and exploration-related effects of pregnanolone were not affected by the &#x03B3;2 inactivation in the cerebellar PCs (<bold>Figure <xref ref-type="fig" rid="F4">4</xref></bold>). The tests should be extended in further studies by using more appropriate neuronal populations for emotional regulation, e.g., in the forebrain.</p>
<p>Learned motor performance depends on cerebellar circuitry. In a recent study, the conditioned eyeblink reflex was pinpointed to deep cerebellar nuclei, particularly the anterior interpositus nuclei, which receive input from cerebellar cortical PCs (<xref ref-type="bibr" rid="B26">Ito, 1984</xref>; <xref ref-type="bibr" rid="B23">Heiney et al., 2014</xref>). PCs have multiple roles in movement precision, including predictive activity and instructive signaling downstream to the deep cerebellar nuclei. Optogenetic activation of PCs-inhibiting interneurons in the molecular layer transiently decreases the constitutive inhibitory output of PCs to the deep cerebellar nuclei and consequently produces precisely timed movement activation in awake mice (<xref ref-type="bibr" rid="B23">Heiney et al., 2014</xref>). Our present findings of enhanced motor impairment by pregnanolone acting on non-synaptic GABA<sub>A</sub> receptors in various cerebellar cortical neuron populations likely resulted from non-timed prolonged disinhibition of the deep cerebellar nuclei.</p>
<p>In Pv-&#x0394;&#x03B3;2 mice the predicted absence of synaptic inhibition with maintained extrasynaptic inhibition in widespread brain regions resulted in a pronounced increase in pregnanolone sensitivity in the rotarod test. Importantly, cerebellar molecular layer interneurons, such as stellate and basket cells are Pv-positive, as are the PCs as well (<xref ref-type="bibr" rid="B38">Meyer et al., 2002</xref>; <xref ref-type="bibr" rid="B28">Kaiser et al., 2015</xref>), and the inhibitory feed-forward control the molecular layer interneurons exert on PCs via synaptic GABA<sub>A</sub> receptors is perforce altered in Pv-&#x0394;&#x03B3;2 mice (<xref ref-type="bibr" rid="B58">Wulff et al., 2009b</xref>). When pregnanolone is administered, it affects the cerebellar function in these knockout mice more strongly than in wild-type mice. Considering that the synaptic inhibitory influence of molecular layer interneurons on PCs is already lacking, the effect of pregnanolone on remaining extrasynaptic receptors in both PCs and stellate/basket cells produces a network inhibitory effect that impairs the learned motor behavior of Pv-&#x0394;&#x03B3;2 mice.</p>
<p>Pregnanolone produced a robustly increased effect on learned motor performance also in Gr-&#x0394;&#x03B3;2 mice. Despite the missing synaptic inhibition from Golgi interneurons to granule cells (correlating with the absence of &#x03B1;1/6&#x03B2;&#x03B3;2 subunit-dependent [<sup>3</sup>H]Ro 15-4513 binding, <bold>Figure <xref ref-type="fig" rid="F2">2A</xref></bold>), these mice learned motor tasks as well as wild-type mice, suggesting compensations. Normally cerebellar granule cells have an excitatory effect on Purkinje cells via parallel fiber axons. When Gr-&#x0394;&#x03B3;2 mice are administered pregnanolone, this excitation is possibly reduced to a greater extent and/or the phasic changes in PC firing are blunted compared to wild-type mice due to the prevalence of only extrasynaptic receptors in the granule cells. The resulting decrease in timed PC activity is a likely explanation for the increased impairing effect of pregnanolone on motor performance. This cerebellar granule-cell specific mouse model revealed that ablation of phasic inhibition only in a single population of cerebellar neurons, although in the most abundant one of the brain, is enough to bring about enhanced neurosteroid sensitivity.</p>
<p>Purkinje cell-&#x0394;&#x03B3;2 mice were previously found to have disrupted inhibitory and excitatory input timing from PCs and mossy fiber collaterals (<xref ref-type="bibr" rid="B58">Wulff et al., 2009b</xref>). The lack of the GABA<sub>A</sub> &#x03B3;2 subunit disrupts the coordination of PC activity through molecular layer interneurons. In the present study powerfully prolonged tonic inhibition of PC activity by pregnanolone acting on extrasynaptic GABA<sub>A</sub> receptors would disrupt the learning and performance of motor tasks more in PC-&#x0394;&#x03B3;2 than in wild-type mice due to the sole availability of presumably &#x03B1;1&#x03B2;2 extrasynaptic receptors. Compensatory mechanisms, such as up-regulation of &#x03B4; subunit expression, cannot be excluded, though. In PC-&#x03B3;2-swap mice the situation was normalized due to the restoration of synaptic GABAergic inhibition in the molecular layer. As compared to the normal &#x03B3;2F77 wild-type mice, the rescue of &#x03B3;2-dependent benzodiazepine site binding in PC-&#x03B3;2-swap was only 23% (<bold>Figure <xref ref-type="fig" rid="F3">3C</xref></bold>), but this comparison may underestimate the rescue, since it does not take into account the binding to molecular layer interneurons missing at the &#x03B3;2I77 background. Anyway, this mouse model with the rescue experiment pinpointed that the presence of &#x03B3;2 subunits and associated synaptic inhibition strongly blunted the effect of pregnanolone on motor performance, underscoring the importance of phasic, directly neurotransmission-linked inhibition. Each PC receives a robust, convergent inhibition from about seven GABAergic, gap-junctionally connected interneurons in the molecular layer (<xref ref-type="bibr" rid="B22">Hausser and Clark, 1997</xref>; <xref ref-type="bibr" rid="B41">Park et al., 2012</xref>; <xref ref-type="bibr" rid="B29">Kim et al., 2014</xref>). The abolition of this phasic function should at least affect the timing of inhibition and thereby the regulation of firing of different PCs and at the end the motor performance. In the absence of &#x03B3;2 subunits, pregnanolone presumably induced prolonged inhibition of PC firing via extrasynaptic receptors. Alternative mechanisms could involve cerebellar glutamatergic N-methyl-D-aspartate receptors that might undergo adaptive changes in neurons with deficient synaptic inhibition [synaptic scaling; cf. (<xref ref-type="bibr" rid="B40">Moykkynen et al., 2007</xref>)], especially as some neurosteroids blunt cerebellar responses to glutamate via potentiating GABA<sub>A</sub> receptor functions or by blocking glutamate receptors (<xref ref-type="bibr" rid="B16">Cauli et al., 2011</xref>; <xref ref-type="bibr" rid="B7">Bali and Jaggi, 2014</xref>; <xref ref-type="bibr" rid="B50">Vyklicky et al., 2015</xref>).</p>
</sec>
<sec><title>Conclusion</title>
<p>Taken as a whole, these results from four different genetically engineered mouse lines with disruptions in the synaptic connections of the cerebellar network point to a delicate balance of inhibitory and excitatory input toward PCs. A possible interpretation of our results is that reduced inhibition from PCs toward the deep cerebellar nuclei, resulting from either decreased excitation (Gr-&#x0394;&#x03B3;2 mice) or increased sustained inhibition of PCs (Pv-&#x0394;&#x03B3;2 and PC-&#x0394;&#x03B3;2 mice), caused the increased effect of pregnanolone on the rotarod test performance. These mouse models may form the basis for studies on molecular mechanisms of neurosteroid actions and for detailed understanding of how the cerebellar cortex regulates motor performance.</p>
</sec>
<sec><title>Author Contributions</title>
<p>EL, A-ML, PW, BL, WW, and EK designed the experiments on mouse models and autoradiography. HL designed and carried out the recombinant receptor study. EL, A-ML, MA, and OV carried out the experiments. All authors wrote and approved the manuscript.</p>
</sec>
<sec><title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> The study was partially funded by the Academy of Finland and the Sigrid Juselius foundation (EK).</p></fn>
</fn-group>
<ack>
<p>We thank Mark Farrant and Stuart Cull-Candy for the support in generating the Gr-&#x0394;&#x03B3;2 mouse line, Hannah Monyer for the PvCre mouse line, and Kerstin L&#x00FC;ddens-D&#x00E4;mgen for technical assistance in recombinant receptor experiments.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abramian</surname> <given-names>A. M.</given-names></name> <name><surname>Comenencia-Ortiz</surname> <given-names>E.</given-names></name> <name><surname>Modgil</surname> <given-names>A.</given-names></name> <name><surname>Vien</surname> <given-names>T. N.</given-names></name> <name><surname>Nakamura</surname> <given-names>Y.</given-names></name> <name><surname>Moore</surname> <given-names>Y. E.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABA<sub>A</sub> receptors.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>111</volume> <fpage>7132</fpage>&#x2013;<lpage>7137</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1403285111</pub-id></citation></ref>
<ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ahboucha</surname> <given-names>S.</given-names></name> <name><surname>Gamrani</surname> <given-names>H.</given-names></name> <name><surname>Baker</surname> <given-names>G.</given-names></name></person-group> (<year>2012</year>). <article-title>GABAergic neurosteroids: the &#x201C;endogenous benzodiazepines&#x201D; of acute liver failure.</article-title> <source><italic>Neurochem. Int.</italic></source> <volume>60</volume> <fpage>707</fpage>&#x2013;<lpage>714</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuint.2011.10.003</pub-id></citation></ref>
<ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aller</surname> <given-names>M. I.</given-names></name> <name><surname>Jones</surname> <given-names>A.</given-names></name> <name><surname>Merlo</surname> <given-names>D.</given-names></name> <name><surname>Paterlini</surname> <given-names>M.</given-names></name> <name><surname>Meyer</surname> <given-names>A. H.</given-names></name> <name><surname>Amtmann</surname> <given-names>U.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Cerebellar granule cell Cre recombinase expression.</article-title> <source><italic>Genesis</italic></source> <volume>36</volume> <fpage>97</fpage>&#x2013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1002/gene.10204</pub-id></citation></ref>
<ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Backstrom</surname> <given-names>T.</given-names></name> <name><surname>Andersson</surname> <given-names>A.</given-names></name> <name><surname>Andree</surname> <given-names>L.</given-names></name> <name><surname>Birzniece</surname> <given-names>V.</given-names></name> <name><surname>Bixo</surname> <given-names>M.</given-names></name> <name><surname>Bjorn</surname> <given-names>I.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Pathogenesis in menstrual cycle-linked CNS disorders.</article-title> <source><italic>Ann. N. Y. Acad. Sci.</italic></source> <volume>1007</volume> <fpage>42</fpage>&#x2013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1286.005</pub-id></citation></ref>
<ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Backstrom</surname> <given-names>T.</given-names></name> <name><surname>Bixo</surname> <given-names>M.</given-names></name> <name><surname>Johansson</surname> <given-names>M.</given-names></name> <name><surname>Nyberg</surname> <given-names>S.</given-names></name> <name><surname>Ossewaarde</surname> <given-names>L.</given-names></name> <name><surname>Ragagnin</surname> <given-names>G.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Allopregnanolone and mood disorders.</article-title> <source><italic>Prog. Neurobiol.</italic></source> <volume>113</volume> <fpage>88</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2013.07.005</pub-id></citation></ref>
<ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Backstrom</surname> <given-names>T.</given-names></name> <name><surname>Haage</surname> <given-names>D.</given-names></name> <name><surname>Lofgren</surname> <given-names>M.</given-names></name> <name><surname>Johansson</surname> <given-names>I. M.</given-names></name> <name><surname>Stromberg</surname> <given-names>J.</given-names></name> <name><surname>Nyberg</surname> <given-names>S.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons.</article-title> <source><italic>Neuroscience</italic></source> <volume>191</volume> <fpage>46</fpage>&#x2013;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.03.061</pub-id></citation></ref>
<ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bali</surname> <given-names>A.</given-names></name> <name><surname>Jaggi</surname> <given-names>A. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Multifunctional aspects of allopregnanolone in stress and related disorders.</article-title> <source><italic>Prog. Neuropsychopharmacol. Biol. Psychiatry</italic></source> <volume>48</volume> <fpage>64</fpage>&#x2013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2013.09.005</pub-id></citation></ref>
<ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barbaccia</surname> <given-names>M. L.</given-names></name></person-group> (<year>2004</year>). <article-title>Neurosteroidogenesis: relevance to neurosteroid actions in brain and modulation by psychotropic drugs.</article-title> <source><italic>Crit. Rev. Neurobiol.</italic></source> <volume>16</volume> <fpage>67</fpage>&#x2013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1615/CritRevNeurobiol.v16.i12.70</pub-id></citation></ref>
<ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barski</surname> <given-names>J. J.</given-names></name> <name><surname>Dethleffsen</surname> <given-names>K.</given-names></name> <name><surname>Meyer</surname> <given-names>M.</given-names></name></person-group> (<year>2000</year>). <article-title>Cre recombinase expression in cerebellar Purkinje cells.</article-title> <source><italic>Genesis</italic></source> <volume>28</volume> <fpage>93</fpage>&#x2013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1002/1526-968X(200011/12)28:3/4&#x003C;93::AID-GENE10>3.3.CO;2-N</pub-id></citation></ref>
<ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baulieu</surname> <given-names>E. E.</given-names></name> <name><surname>Robel</surname> <given-names>P.</given-names></name> <name><surname>Schumacher</surname> <given-names>M.</given-names></name></person-group> (<year>2001</year>). <article-title>Neurosteroids: beginning of the story.</article-title> <source><italic>Int. Rev. Neurobiol.</italic></source> <volume>46</volume> <fpage>1</fpage>&#x2013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/S0074-7742(01)46057-0</pub-id></citation></ref>
<ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belelli</surname> <given-names>D.</given-names></name> <name><surname>Casula</surname> <given-names>A.</given-names></name> <name><surname>Ling</surname> <given-names>A.</given-names></name> <name><surname>Lambert</surname> <given-names>J. J.</given-names></name></person-group> (<year>2002</year>). <article-title>The influence of subunit composition on the interaction of neurosteroids with GABA(A) receptors.</article-title> <source><italic>Neuropharmacology</italic></source> <volume>43</volume> <fpage>651</fpage>&#x2013;<lpage>661</lpage>. <pub-id pub-id-type="doi">10.1016/S0028-3908(02)00172-7</pub-id></citation></ref>
<ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Belelli</surname> <given-names>D.</given-names></name> <name><surname>Herd</surname> <given-names>M. B.</given-names></name> <name><surname>Mitchell</surname> <given-names>E. A.</given-names></name> <name><surname>Peden</surname> <given-names>D. R.</given-names></name> <name><surname>Vardy</surname> <given-names>A. W.</given-names></name> <name><surname>Gentet</surname> <given-names>L.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Neuroactive steroids and inhibitory neurotransmission: mechanisms of action and physiological relevance.</article-title> <source><italic>Neuroscience</italic></source> <volume>138</volume> <fpage>821</fpage>&#x2013;<lpage>829</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2005.07.021</pub-id></citation></ref>
<ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bengtsson</surname> <given-names>S. K.</given-names></name> <name><surname>Johansson</surname> <given-names>M.</given-names></name> <name><surname>Backstrom</surname> <given-names>T.</given-names></name> <name><surname>Nitsch</surname> <given-names>R. M.</given-names></name> <name><surname>Wang</surname> <given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Brief but chronic increase in allopregnanolone cause accelerated AD pathology differently in two mouse models.</article-title> <source><italic>Curr. Alzheimer Res.</italic></source> <volume>10</volume> <fpage>38</fpage>&#x2013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.2174/156720513804871363</pub-id></citation></ref>
<ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bengtsson</surname> <given-names>S. K.</given-names></name> <name><surname>Johansson</surname> <given-names>M.</given-names></name> <name><surname>Backstrom</surname> <given-names>T.</given-names></name> <name><surname>Wang</surname> <given-names>M.</given-names></name></person-group> (<year>2012</year>). <article-title>Chronic allopregnanolone treatment accelerates Alzheimer&#x2019;s disease development in AbetaPP(Swe)PSEN1(DeltaE9) mice.</article-title> <source><italic>J. Alzheimers. Dis.</italic></source> <volume>31</volume> <fpage>71</fpage>&#x2013;<lpage>84</lpage>.</citation></ref>
<ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carver</surname> <given-names>C. M.</given-names></name> <name><surname>Wu</surname> <given-names>X.</given-names></name> <name><surname>Gangisetty</surname> <given-names>O.</given-names></name> <name><surname>Reddy</surname> <given-names>D. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Perimenstrual-like hormonal regulation of extrasynaptic delta-containing GABA<sub>A</sub> receptors mediating tonic inhibition and neurosteroid sensitivity.</article-title> <source><italic>J. Neurosci.</italic></source> <volume>34</volume> <fpage>14181</fpage>&#x2013;<lpage>14197</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.0596-14.2014</pub-id></citation></ref>
<ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cauli</surname> <given-names>O.</given-names></name> <name><surname>Gonzalez-Usano</surname> <given-names>A.</given-names></name> <name><surname>Agusti</surname> <given-names>A.</given-names></name> <name><surname>Felipo</surname> <given-names>V.</given-names></name></person-group> (<year>2011</year>). <article-title>Differential modulation of the glutamate-nitric oxide-cyclic GMP pathway by distinct neurosteroids in cerebellum in vivo.</article-title> <source><italic>Neuroscience</italic></source> <volume>190</volume> <fpage>27</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.06.009</pub-id></citation></ref>
<ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cope</surname> <given-names>D. W.</given-names></name> <name><surname>Halbsguth</surname> <given-names>C.</given-names></name> <name><surname>Karayannis</surname> <given-names>T.</given-names></name> <name><surname>Wulff</surname> <given-names>P.</given-names></name> <name><surname>Ferraguti</surname> <given-names>F.</given-names></name> <name><surname>Hoeger</surname> <given-names>H.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Loss of zolpidem efficacy in the hippocampus of mice with the GABA<sub>A</sub> receptor gamma2 F77I point mutation.</article-title> <source><italic>Eur. J. Neurosci.</italic></source> <volume>21</volume> <fpage>3002</fpage>&#x2013;<lpage>3016</lpage>. <pub-id pub-id-type="doi">10.1111/j.1460-9568.2005.04127.x</pub-id></citation></ref>
<ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cope</surname> <given-names>D. W.</given-names></name> <name><surname>Wulff</surname> <given-names>P.</given-names></name> <name><surname>Oberto</surname> <given-names>A.</given-names></name> <name><surname>Aller</surname> <given-names>M. I.</given-names></name> <name><surname>Capogna</surname> <given-names>M.</given-names></name> <name><surname>Ferraguti</surname> <given-names>F.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Abolition of zolpidem sensitivity in mice with a point mutation in the GABA<sub>A</sub> receptor gamma2 subunit.</article-title> <source><italic>Neuropharmacology</italic></source> <volume>47</volume> <fpage>17</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.03.007</pub-id></citation></ref>
<ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crestani</surname> <given-names>F.</given-names></name> <name><surname>Lorez</surname> <given-names>M.</given-names></name> <name><surname>Baer</surname> <given-names>K.</given-names></name> <name><surname>Essrich</surname> <given-names>C.</given-names></name> <name><surname>Benke</surname> <given-names>D.</given-names></name> <name><surname>Laurent</surname> <given-names>J. P.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Decreased GABA<sub>A</sub>-receptor clustering results in enhanced anxiety and a bias for threat cues.</article-title> <source><italic>Nat. Neurosci.</italic></source> <volume>2</volume> <fpage>833</fpage>&#x2013;<lpage>839</lpage>. <pub-id pub-id-type="doi">10.1038/12207</pub-id></citation></ref>
<ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fuchs</surname> <given-names>E. C.</given-names></name> <name><surname>Zivkovic</surname> <given-names>A. R.</given-names></name> <name><surname>Cunningham</surname> <given-names>M. O.</given-names></name> <name><surname>Middleton</surname> <given-names>S.</given-names></name> <name><surname>Lebeau</surname> <given-names>F. E.</given-names></name> <name><surname>Bannerman</surname> <given-names>D. M.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Recruitment of parvalbumin-positive interneurons determines hippocampal function and associated behavior.</article-title> <source><italic>Neuron</italic></source> <volume>53</volume> <fpage>591</fpage>&#x2013;<lpage>604</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2007.01.031</pub-id></citation></ref>
<ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gunther</surname> <given-names>U.</given-names></name> <name><surname>Benson</surname> <given-names>J.</given-names></name> <name><surname>Benke</surname> <given-names>D.</given-names></name> <name><surname>Fritschy</surname> <given-names>J. M.</given-names></name> <name><surname>Reyes</surname> <given-names>G.</given-names></name> <name><surname>Knoflach</surname> <given-names>F.</given-names></name><etal/></person-group> (<year>1995</year>). <article-title>Benzodiazepine-insensitive mice generated by targeted disruption of the gamma 2 subunit gene of gamma-aminobutyric acid type a receptors.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>92</volume> <fpage>7749</fpage>&#x2013;<lpage>7753</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.92.17.7749</pub-id></citation></ref>
<ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hausser</surname> <given-names>M.</given-names></name> <name><surname>Clark</surname> <given-names>B. A.</given-names></name></person-group> (<year>1997</year>). <article-title>Tonic synaptic inhibition modulates neuronal output pattern and spatiotemporal synaptic integration.</article-title> <source><italic>Neuron</italic></source> <volume>19</volume> <fpage>665</fpage>&#x2013;<lpage>678</lpage>. <pub-id pub-id-type="doi">10.1016/S0896-6273(00)80379-7</pub-id></citation></ref>
<ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heiney</surname> <given-names>S. A.</given-names></name> <name><surname>Kim</surname> <given-names>J.</given-names></name> <name><surname>Augustine</surname> <given-names>G. J.</given-names></name> <name><surname>Medina</surname> <given-names>J. F.</given-names></name></person-group> (<year>2014</year>). <article-title>Precise control of movement kinematics by optogenetic inhibition of Purkinje cell activity.</article-title> <source><italic>J. Neurosci.</italic></source> <volume>34</volume> <fpage>2321</fpage>&#x2013;<lpage>2330</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.4547-13.2014</pub-id></citation></ref>
<ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hosie</surname> <given-names>A. M.</given-names></name> <name><surname>Clarke</surname> <given-names>L.</given-names></name> <name><surname>da Silva</surname> <given-names>H.</given-names></name> <name><surname>Smart</surname> <given-names>T. G.</given-names></name></person-group> (<year>2009</year>). <article-title>Conserved site for neurosteroid modulation of GABA a receptors.</article-title> <source><italic>Neuropharmacology</italic></source> <volume>56</volume> <fpage>149</fpage>&#x2013;<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.07.050</pub-id></citation></ref>
<ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hosie</surname> <given-names>A. M.</given-names></name> <name><surname>Wilkins</surname> <given-names>M. E.</given-names></name> <name><surname>da Silva</surname> <given-names>H. M.</given-names></name> <name><surname>Smart</surname> <given-names>T. G.</given-names></name></person-group> (<year>2006</year>). <article-title>Endogenous neurosteroids regulate GABA<sub>A</sub> receptors through two discrete transmembrane sites.</article-title> <source><italic>Nature</italic></source> <volume>444</volume> <fpage>486</fpage>&#x2013;<lpage>489</lpage>. <pub-id pub-id-type="doi">10.1038/nature05324</pub-id></citation></ref>
<ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname> <given-names>M.</given-names></name></person-group> (<year>1984</year>). <source><italic>The Cerebellum and Neural Control.</italic></source> <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Raven Press</publisher-name>.</citation></ref>
<ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname> <given-names>M.</given-names></name> <name><surname>Schallhorn</surname> <given-names>A.</given-names></name> <name><surname>Wurm</surname> <given-names>F. M.</given-names></name></person-group> (<year>1996</year>). <article-title>Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation.</article-title> <source><italic>Nucleic Acids Res.</italic></source> <volume>24</volume> <fpage>596</fpage>&#x2013;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1093/nar/24.4.596</pub-id></citation></ref>
<ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaiser</surname> <given-names>T.</given-names></name> <name><surname>Ting</surname> <given-names>J. T.</given-names></name> <name><surname>Monteiro</surname> <given-names>P.</given-names></name> <name><surname>Feng</surname> <given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Transgenic labeling of parvalbumin-expressing neurons with tdTomato.</article-title> <source><italic>Neuroscience</italic></source> <volume>21</volume> <fpage>236</fpage>&#x2013;<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.08.036</pub-id></citation></ref>
<ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname> <given-names>J.</given-names></name> <name><surname>Lee</surname> <given-names>S.</given-names></name> <name><surname>Tsuda</surname> <given-names>S.</given-names></name> <name><surname>Zhang</surname> <given-names>X.</given-names></name> <name><surname>Asrican</surname> <given-names>B.</given-names></name> <name><surname>Gloss</surname> <given-names>B.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Optogenetic mapping of cerebellar inhibitory circuitry reveals spatially biased coordination of interneurons via electrical synapses.</article-title> <source><italic>Cell Rep.</italic></source> <volume>7</volume> <fpage>1601</fpage>&#x2013;<lpage>1613</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2014.04.047</pub-id></citation></ref>
<ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korpi</surname> <given-names>E. R.</given-names></name> <name><surname>Koikkalainen</surname> <given-names>P.</given-names></name> <name><surname>Vekovischeva</surname> <given-names>O. Y.</given-names></name> <name><surname>Makela</surname> <given-names>R.</given-names></name> <name><surname>Kleinz</surname> <given-names>R.</given-names></name> <name><surname>Uusi-Oukari</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Cerebellar granule-cell-specific GABA<sub>A</sub> receptors attenuate benzodiazepine-induced ataxia: evidence from alpha 6-subunit-deficient mice.</article-title> <source><italic>Eur. J. Neurosci.</italic></source> <volume>11</volume> <fpage>233</fpage>&#x2013;<lpage>240</lpage>. <pub-id pub-id-type="doi">10.1046/j.1460-9568.1999.00421.x</pub-id></citation></ref>
<ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korpi</surname> <given-names>E. R.</given-names></name> <name><surname>Luddens</surname> <given-names>H.</given-names></name></person-group> (<year>1997</year>). <article-title>Furosemide interactions with brain GABA<sub>A</sub> receptors.</article-title> <source><italic>Br. J. Pharmacol.</italic></source> <volume>120</volume> <fpage>741</fpage>&#x2013;<lpage>748</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjp.0700922</pub-id></citation></ref>
<ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leppa</surname> <given-names>E.</given-names></name> <name><surname>Linden</surname> <given-names>A. M.</given-names></name> <name><surname>Vekovischeva</surname> <given-names>O. Y.</given-names></name> <name><surname>Swinny</surname> <given-names>J. D.</given-names></name> <name><surname>Rantanen</surname> <given-names>V.</given-names></name> <name><surname>Toppila</surname> <given-names>E.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Removal of GABA(A) receptor gamma2 subunits from parvalbumin neurons causes wide-ranging behavioral alterations.</article-title> <source><italic>PLoS ONE</italic></source> <volume>6</volume>:<issue>e24159</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0024159</pub-id></citation></ref>
<ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leppa</surname> <given-names>E.</given-names></name> <name><surname>Vekovischeva</surname> <given-names>O. Y.</given-names></name> <name><surname>Linden</surname> <given-names>A. M.</given-names></name> <name><surname>Wulff</surname> <given-names>P.</given-names></name> <name><surname>Oberto</surname> <given-names>A.</given-names></name> <name><surname>Wisden</surname> <given-names>W.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Agonistic effects of the beta-carboline DMCM revealed in GABA(A) receptor gamma 2 subunit F77I point-mutated mice.</article-title> <source><italic>Neuropharmacology</italic></source> <volume>48</volume> <fpage>469</fpage>&#x2013;<lpage>478</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2004.11.007</pub-id></citation></ref>
<ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Linden</surname> <given-names>A. M.</given-names></name> <name><surname>Schmitt</surname> <given-names>U.</given-names></name> <name><surname>Leppa</surname> <given-names>E.</given-names></name> <name><surname>Wulff</surname> <given-names>P.</given-names></name> <name><surname>Wisden</surname> <given-names>W.</given-names></name> <name><surname>Luddens</surname> <given-names>H.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Ro 15-4513 antagonizes alcohol-induced sedation in mice through alphabetagamma2-type GABA(A) receptors.</article-title> <source><italic>Front. Neurosci.</italic></source> <volume>5</volume>:<issue>3</issue>. <pub-id pub-id-type="doi">10.3389/fnins.2011.00003</pub-id></citation></ref>
<ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mackenzie</surname> <given-names>G.</given-names></name> <name><surname>Maguire</surname> <given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>The role of ovarian hormone-derived neurosteroids on the regulation of GABA receptors in affective disorders.</article-title> <source><italic>Psychopharmacology (Berl.)</italic></source> <volume>231</volume> <fpage>3333</fpage>&#x2013;<lpage>3342</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-013-3423-z</pub-id></citation></ref>
<ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maguire</surname> <given-names>J. L.</given-names></name> <name><surname>Stell</surname> <given-names>B. M.</given-names></name> <name><surname>Rafizadeh</surname> <given-names>M.</given-names></name> <name><surname>Mody</surname> <given-names>I.</given-names></name></person-group> (<year>2005</year>). <article-title>Ovarian cycle-linked changes in GABA(A) receptors mediating tonic inhibition alter seizure susceptibility and anxiety.</article-title> <source><italic>Nat. Neurosci.</italic></source> <volume>8</volume> <fpage>797</fpage>&#x2013;<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1038/nn1469</pub-id></citation></ref>
<ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Makela</surname> <given-names>R.</given-names></name> <name><surname>Uusi-Oukari</surname> <given-names>M.</given-names></name> <name><surname>Homanics</surname> <given-names>G. E.</given-names></name> <name><surname>Quinlan</surname> <given-names>J. J.</given-names></name> <name><surname>Firestone</surname> <given-names>L. L.</given-names></name> <name><surname>Wisden</surname> <given-names>W.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>Cerebellar gamma-aminobutyric acid type a receptors: pharmacological subtypes revealed by mutant mouse lines.</article-title> <source><italic>Mol. Pharmacol.</italic></source> <volume>52</volume> <fpage>380</fpage>&#x2013;<lpage>388</lpage>.</citation></ref>
<ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname> <given-names>A. H.</given-names></name> <name><surname>Katona</surname> <given-names>I.</given-names></name> <name><surname>Blatow</surname> <given-names>M.</given-names></name> <name><surname>Rozov</surname> <given-names>A.</given-names></name> <name><surname>Monyer</surname> <given-names>H.</given-names></name></person-group> (<year>2002</year>). <article-title>In vivo labeling of parvalbumin-positive interneurons and analysis of electrical coupling in identified neurons.</article-title> <source><italic>J. Neurosci.</italic></source> <volume>22</volume> <fpage>7055</fpage>&#x2013;<lpage>7064</lpage>.</citation></ref>
<ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mihalek</surname> <given-names>R. M.</given-names></name> <name><surname>Banerjee</surname> <given-names>P. K.</given-names></name> <name><surname>Korpi</surname> <given-names>E. R.</given-names></name> <name><surname>Quinlan</surname> <given-names>J. J.</given-names></name> <name><surname>Firestone</surname> <given-names>L. L.</given-names></name> <name><surname>Mi</surname> <given-names>Z. P.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>96</volume> <fpage>12905</fpage>&#x2013;<lpage>12910</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.96.22.12905</pub-id></citation></ref>
<ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moykkynen</surname> <given-names>T. P.</given-names></name> <name><surname>Sinkkonen</surname> <given-names>S. T.</given-names></name> <name><surname>Korpi</surname> <given-names>E. R.</given-names></name></person-group> (<year>2007</year>). <article-title>Compensation by reduced L-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor responses in a mouse model with reduced gamma-aminobutyric acid type a receptor-mediated synaptic inhibition.</article-title> <source><italic>J. Neurosci. Res.</italic></source> <volume>85</volume> <fpage>668</fpage>&#x2013;<lpage>672</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.21138</pub-id></citation></ref>
<ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Park</surname> <given-names>S. M.</given-names></name> <name><surname>Tara</surname> <given-names>E.</given-names></name> <name><surname>Khodakhah</surname> <given-names>K.</given-names></name></person-group> (<year>2012</year>). <article-title>Efficient generation of reciprocal signals by inhibition.</article-title> <source><italic>J. Neurophysiol.</italic></source> <volume>107</volume> <fpage>2453</fpage>&#x2013;<lpage>2462</lpage>. <pub-id pub-id-type="doi">10.1152/jn.00083.2012</pub-id></citation></ref>
<ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pritchett</surname> <given-names>D. B.</given-names></name> <name><surname>Seeburg</surname> <given-names>P. H.</given-names></name></person-group> (<year>1990</year>). <article-title>Gamma-aminobutyric acidA receptor alpha 5-subunit creates novel type II benzodiazepine receptor pharmacology.</article-title> <source><italic>J. Neurochem.</italic></source> <volume>54</volume> <fpage>1802</fpage>&#x2013;<lpage>1804</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.1990.tb01237.x</pub-id></citation></ref>
<ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saarelainen</surname> <given-names>K. S.</given-names></name> <name><surname>Ranna</surname> <given-names>M.</given-names></name> <name><surname>Rabe</surname> <given-names>H.</given-names></name> <name><surname>Sinkkonen</surname> <given-names>S. T.</given-names></name> <name><surname>Moykkynen</surname> <given-names>T.</given-names></name> <name><surname>Uusi-Oukari</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Enhanced behavioral sensitivity to the competitive GABA agonist, gaboxadol, in transgenic mice over-expressing hippocampal extrasynaptic alph&#x03B1;6beta GABA(A) receptors.</article-title> <source><italic>J. Neurochem.</italic></source> <volume>105</volume> <fpage>338</fpage>&#x2013;<lpage>350</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2007.05136.x</pub-id></citation></ref>
<ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schweizer</surname> <given-names>C.</given-names></name> <name><surname>Balsiger</surname> <given-names>S.</given-names></name> <name><surname>Bluethmann</surname> <given-names>H.</given-names></name> <name><surname>Mansuy</surname> <given-names>I. M.</given-names></name> <name><surname>Fritschy</surname> <given-names>J. M.</given-names></name> <name><surname>Mohler</surname> <given-names>H.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>The gamma 2 subunit of GABA(A) receptors is required for maintenance of receptors at mature synapses.</article-title> <source><italic>Mol. Cell. Neurosci.</italic></source> <volume>24</volume> <fpage>442</fpage>&#x2013;<lpage>450</lpage>. <pub-id pub-id-type="doi">10.1016/S1044-7431(03)00202-1</pub-id></citation></ref>
<ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sieghart</surname> <given-names>W.</given-names></name></person-group> (<year>1995</year>). <article-title>Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.</article-title> <source><italic>Pharmacol. Rev.</italic></source> <volume>47</volume> <fpage>181</fpage>&#x2013;<lpage>234</lpage>.</citation></ref>
<ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spigelman</surname> <given-names>I.</given-names></name> <name><surname>Li</surname> <given-names>Z.</given-names></name> <name><surname>Liang</surname> <given-names>J.</given-names></name> <name><surname>Cagetti</surname> <given-names>E.</given-names></name> <name><surname>Samzadeh</surname> <given-names>S.</given-names></name> <name><surname>Mihalek</surname> <given-names>R. M.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>Reduced inhibition and sensitivity to neurosteroids in hippocampus of mice lacking the GABA(A) receptor delta subunit.</article-title> <source><italic>J. Neurophysiol.</italic></source> <volume>90</volume> <fpage>903</fpage>&#x2013;<lpage>910</lpage>. <pub-id pub-id-type="doi">10.1152/jn.01022.2002</pub-id></citation></ref>
<ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stell</surname> <given-names>B. M.</given-names></name> <name><surname>Brickley</surname> <given-names>S. G.</given-names></name> <name><surname>Tang</surname> <given-names>C. Y.</given-names></name> <name><surname>Farrant</surname> <given-names>M.</given-names></name> <name><surname>Mody</surname> <given-names>I.</given-names></name></person-group> (<year>2003</year>). <article-title>Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABA<sub>A</sub> receptors.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>100</volume> <fpage>14439</fpage>&#x2013;<lpage>14444</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2435457100</pub-id></citation></ref>
<ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uusi-Oukari</surname> <given-names>M.</given-names></name> <name><surname>Korpi</surname> <given-names>E. R.</given-names></name></person-group> (<year>2010</year>). <article-title>Regulation of GABA(A) receptor subunit expression by pharmacological agents.</article-title> <source><italic>Pharmacol. Rev.</italic></source> <volume>62</volume> <fpage>97</fpage>&#x2013;<lpage>135</lpage>. <pub-id pub-id-type="doi">10.1124/pr.109.002063</pub-id></citation></ref>
<ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Broekhoven</surname> <given-names>F.</given-names></name> <name><surname>Verkes</surname> <given-names>R. J.</given-names></name></person-group> (<year>2003</year>). <article-title>Neurosteroids in depression: a review.</article-title> <source><italic>Psychopharmacology (Berl.)</italic></source> <volume>165</volume> <fpage>97</fpage>&#x2013;<lpage>110</lpage>.</citation></ref>
<ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vyklicky</surname> <given-names>V.</given-names></name> <name><surname>Krausova</surname> <given-names>B.</given-names></name> <name><surname>Cerny</surname> <given-names>J.</given-names></name> <name><surname>Balik</surname> <given-names>A.</given-names></name> <name><surname>Zapotocky</surname> <given-names>M.</given-names></name> <name><surname>Novotny</surname> <given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Block of NMDA receptor channels by endogenous neurosteroids: implications for the agonist induced conformational states of the channel vestibule.</article-title> <source><italic>Sci. Rep.</italic></source> <volume>5</volume>:<issue>10935</issue>. <pub-id pub-id-type="doi">10.1038/srep10935</pub-id></citation></ref>
<ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J. M.</given-names></name> <name><surname>Singh</surname> <given-names>C.</given-names></name> <name><surname>Liu</surname> <given-names>L.</given-names></name> <name><surname>Irwin</surname> <given-names>R. W.</given-names></name> <name><surname>Chen</surname> <given-names>S.</given-names></name> <name><surname>Chung</surname> <given-names>E. J.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer&#x2019;s disease.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>107</volume> <fpage>6498</fpage>&#x2013;<lpage>6503</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1001422107</pub-id></citation></ref>
<ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wisden</surname> <given-names>W.</given-names></name> <name><surname>Korpi</surname> <given-names>E. R.</given-names></name> <name><surname>Bahn</surname> <given-names>S.</given-names></name></person-group> (<year>1996</year>). <article-title>The cerebellum: a model system for studying GABA<sub>A</sub> receptor diversity.</article-title> <source><italic>Neuropharmacology</italic></source> <volume>35</volume> <fpage>1139</fpage>&#x2013;<lpage>1160</lpage>. <pub-id pub-id-type="doi">10.1016/S0028-3908(96)00076-7</pub-id></citation></ref>
<ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wisden</surname> <given-names>W.</given-names></name> <name><surname>Murray</surname> <given-names>A. J.</given-names></name> <name><surname>McClure</surname> <given-names>C.</given-names></name> <name><surname>Wulff</surname> <given-names>P.</given-names></name></person-group> (<year>2009</year>). <article-title>Studying cerebellar circuits by remote control of selected neuronal types with GABA(A) receptors.</article-title> <source><italic>Front. Mol. Neurosci.</italic></source> <volume>2</volume>:<issue>29</issue>. <pub-id pub-id-type="doi">10.3389/neuro.02.029.2009</pub-id></citation></ref>
<ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wohlfarth</surname> <given-names>K. M.</given-names></name> <name><surname>Bianchi</surname> <given-names>M. T.</given-names></name> <name><surname>Macdonald</surname> <given-names>R. L.</given-names></name></person-group> (<year>2002</year>). <article-title>Enhanced neurosteroid potentiation of ternary GABA(A) receptors containing the delta subunit.</article-title> <source><italic>J. Neurosci.</italic></source> <volume>22</volume> <fpage>1541</fpage>&#x2013;<lpage>1549</lpage>.</citation></ref>
<ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>X.</given-names></name> <name><surname>Gangisetty</surname> <given-names>O.</given-names></name> <name><surname>Carver</surname> <given-names>C. M.</given-names></name> <name><surname>Reddy</surname> <given-names>D. S.</given-names></name></person-group> (<year>2013</year>). <article-title>Estrous cycle regulation of extrasynaptic delta-containing GABA(A) receptor-mediated tonic inhibition and limbic epileptogenesis.</article-title> <source><italic>J. Pharmacol. Exp. Ther.</italic></source> <volume>346</volume> <fpage>146</fpage>&#x2013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.113.203653</pub-id></citation></ref>
<ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wulff</surname> <given-names>P.</given-names></name> <name><surname>Goetz</surname> <given-names>T.</given-names></name> <name><surname>Leppa</surname> <given-names>E.</given-names></name> <name><surname>Linden</surname> <given-names>A. M.</given-names></name> <name><surname>Renzi</surname> <given-names>M.</given-names></name> <name><surname>Swinny</surname> <given-names>J. D.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>From synapse to behavior: rapid modulation of defined neuronal types with engineered GABA<sub>A</sub> receptors.</article-title> <source><italic>Nat. Neurosci.</italic></source> <volume>10</volume> <fpage>923</fpage>&#x2013;<lpage>929</lpage>. <pub-id pub-id-type="doi">10.1038/nn1927</pub-id></citation></ref>
<ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wulff</surname> <given-names>P.</given-names></name> <name><surname>Ponomarenko</surname> <given-names>A. A.</given-names></name> <name><surname>Bartos</surname> <given-names>M.</given-names></name> <name><surname>Korotkova</surname> <given-names>T. M.</given-names></name> <name><surname>Fuchs</surname> <given-names>E. C.</given-names></name> <name><surname>Bahner</surname> <given-names>F.</given-names></name><etal/></person-group> (<year>2009a</year>). <article-title>Hippocampal theta rhythm and its coupling with gamma oscillations require fast inhibition onto parvalbumin-positive interneurons.</article-title> <source><italic>Proc. Natl. Acad. Sci. U.S.A.</italic></source> <volume>106</volume> <fpage>3561</fpage>&#x2013;<lpage>3566</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0813176106</pub-id></citation></ref>
<ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wulff</surname> <given-names>P.</given-names></name> <name><surname>Schonewille</surname> <given-names>M.</given-names></name> <name><surname>Renzi</surname> <given-names>M.</given-names></name> <name><surname>Viltono</surname> <given-names>L.</given-names></name> <name><surname>Sassoe-Pognetto</surname> <given-names>M.</given-names></name> <name><surname>Badura</surname> <given-names>A.</given-names></name><etal/></person-group> (<year>2009b</year>). <article-title>Synaptic inhibition of Purkinje cells mediates consolidation of vestibulo-cerebellar motor learning.</article-title> <source><italic>Nat. Neurosci.</italic></source> <volume>12</volume> <fpage>1042</fpage>&#x2013;<lpage>1049</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2348</pub-id></citation></ref>
<ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>P.</given-names></name> <name><surname>Xie</surname> <given-names>M. Q.</given-names></name> <name><surname>Ding</surname> <given-names>Y. Q.</given-names></name> <name><surname>Liao</surname> <given-names>M.</given-names></name> <name><surname>Qi</surname> <given-names>S. S.</given-names></name> <name><surname>Chen</surname> <given-names>S. X.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice.</article-title> <source><italic>Neuroscience</italic></source> <volume>290</volume> <fpage>214</fpage>&#x2013;<lpage>226</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.01.019</pub-id></citation></ref>
</ref-list>
</back>
</article>